A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis

Gastroenterol Hepatol. 2022 Dec;45(10):780-781. doi: 10.1016/j.gastrohep.2022.02.008. Epub 2022 Mar 10.

[Article in English, Spanish]

Authors

Alexandra Ruiz-Cerulla¹, Lorena Rodríguez-Alonso², Francisco Rodríguez-Moranta², Jordi Guardiola²

Affiliations

¹ Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: aruizcerulla@bellvitgehospital.cat.
² Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

PMID: 35278502
DOI: 10.1016/j.gastrohep.2022.02.008

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / therapeutic use
Colitis, Ulcerative* / drug therapy
Humans
Mesalamine
Remission Induction
Sulfasalazine
Treatment Outcome

Substances

Adalimumab
Mesalamine
Sulfasalazine